MX341368B - Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn. - Google Patents

Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn.

Info

Publication number
MX341368B
MX341368B MX2011010675A MX2011010675A MX341368B MX 341368 B MX341368 B MX 341368B MX 2011010675 A MX2011010675 A MX 2011010675A MX 2011010675 A MX2011010675 A MX 2011010675A MX 341368 B MX341368 B MX 341368B
Authority
MX
Mexico
Prior art keywords
inhibitors
dna damaging
damaging agents
checkpoint kinase
potentiating
Prior art date
Application number
MX2011010675A
Other languages
English (en)
Other versions
MX2011010675A (es
Inventor
Michael J Humphries
Shannon L Winski
Original Assignee
Array Biopharma Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc * filed Critical Array Biopharma Inc *
Publication of MX2011010675A publication Critical patent/MX2011010675A/es
Publication of MX341368B publication Critical patent/MX341368B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un inhibidor de CHK 1 para administración a un paciente con cáncer para potenciar un agente dañino de ADN.
MX2011010675A 2009-04-11 2010-04-09 Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn. MX341368B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16856309P 2009-04-11 2009-04-11
PCT/US2010/030634 WO2010118390A1 (en) 2009-04-11 2010-04-09 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents

Publications (2)

Publication Number Publication Date
MX2011010675A MX2011010675A (es) 2012-03-16
MX341368B true MX341368B (es) 2016-08-17

Family

ID=42651200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010675A MX341368B (es) 2009-04-11 2010-04-09 Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn.

Country Status (15)

Country Link
EP (1) EP2416773B1 (es)
JP (2) JP5805071B2 (es)
KR (1) KR101676062B1 (es)
CN (1) CN102612365B (es)
AU (1) AU2010233122B2 (es)
BR (1) BRPI1013920A2 (es)
CA (1) CA2758300C (es)
ES (1) ES2608656T3 (es)
IL (1) IL215709A (es)
MX (1) MX341368B (es)
NZ (1) NZ596125A (es)
RU (1) RU2567044C2 (es)
SG (3) SG10201404012RA (es)
WO (1) WO2010118390A1 (es)
ZA (1) ZA201108273B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
WO2015053402A1 (ja) 2013-10-11 2015-04-16 国立大学法人東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2020150417A2 (en) * 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR102285996B1 (ko) * 2019-08-08 2021-08-05 차의과학대학교 산학협력단 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도
WO2021113661A1 (en) 2019-12-05 2021-06-10 Seagen Inc. Amorphous and polymorphic form of a specific chk1 inhibitor
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US20090312280A1 (en) * 2006-04-04 2009-12-17 Pfizer Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
WO2008063558A2 (en) * 2006-11-17 2008-05-29 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.

Also Published As

Publication number Publication date
CA2758300A1 (en) 2010-10-14
AU2010233122B2 (en) 2015-09-17
ES2608656T3 (es) 2017-04-12
RU2567044C2 (ru) 2015-10-27
CN102612365B (zh) 2017-04-12
CN102612365A (zh) 2012-07-25
EP2416773B1 (en) 2016-09-28
JP5805071B2 (ja) 2015-11-04
NZ596125A (en) 2012-08-31
SG175242A1 (en) 2011-11-28
CA2758300C (en) 2017-07-25
JP2014198741A (ja) 2014-10-23
SG10201404012RA (en) 2014-09-26
ZA201108273B (en) 2013-07-31
WO2010118390A1 (en) 2010-10-14
IL215709A (en) 2017-06-29
EP2416773A1 (en) 2012-02-15
JP2012523435A (ja) 2012-10-04
MX2011010675A (es) 2012-03-16
BRPI1013920A2 (pt) 2016-04-05
RU2011145773A (ru) 2013-05-20
SG10201900212QA (en) 2019-02-27
AU2010233122A1 (en) 2011-11-24
KR20120004523A (ko) 2012-01-12
IL215709A0 (en) 2012-01-31
KR101676062B1 (ko) 2016-11-14

Similar Documents

Publication Publication Date Title
MX341368B (es) Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
UA115320C2 (uk) Інгібітори кінази
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
MX2009009786A (es) Inhibidores de la via de hedgehog.
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TN2011000293A1 (en) Protein kinase inhibitors
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
AU2012214029A8 (en) Rorgammat inhibitors
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
MX343669B (es) Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
EP2254411A4 (en) COMPLEMENT INHIBITORS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
IN2012DN00765A (es)
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
IN2012DN02816A (es)
MX2015012386A (es) Inhibidores de la cinasa cdk9.
WO2011038924A3 (en) Proteasome inhibitors for treating cancer
ES2530755T3 (es) Terapia de combinación para el tratamiento del cáncer
ES2530436T3 (es) Combinación

Legal Events

Date Code Title Description
FG Grant or registration